Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 1, 2013, Pages 36-42

  Sakamoto, Maiko ^a   Marcotte, Thomas D ^a   Umlauf, Anya ^a   Franklin, Donald ^a   Heaton, Robert K ^a   Ellis, Ronald J ^b   Letendre, Scott ^c   Alexander, Terry ^a   McCutchan, J A ^c   Morgan, Erin E ^a   Woods, Steven P ^a   Collier, Ann C ^d   Marra, Christina M ^d   Clifford, David B ^e   Gelman, Benjamin B ^f   McArthur, Justin C ^g   Morgello, Susan ^h   Simpson, David ^h   Grant, Igor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cognition; HIV; HIV dementia scale; HIV associated neurocognitive disorders; screening measures

Indexed keywords

ACCURACY; ADULT; ARTICLE; ATTENTION; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HIV ASSOCIATED DEMENTIA; HIV DEMENTIA SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RATING SCALE; RECALL; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AIDS DEMENTIA COMPLEX; CLINICAL MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 84872093296     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318278ffa4     Document Type: Article

References (42)

1. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-1799.
2. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-2096.
3. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3-10.
4. McArthur JC, Brew BJ. HIV-associated neurocognitive disorders: is there a hidden epidemic? AIDS. 2010;24:1367-1370.
5. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
6. Power C, Selnes OA, Grim JA, et al. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8: 273-278.
7. Berghuis JP, Uldall KK, Lalonde B. Validity of two scales in identifying HIV-associated dementia. J Acquir Immune Defic Syndr. 1999;21:134-140.
8. Bottiggi KA, Chang JJ, Schmitt FA, et al. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci. 2007;260: 11-15.
9. Dougherty RH, Skolasky RL Jr, McArthur JC. Progression of HIVassociated dementia treated with HAART. AIDS Read. 2002;12:69-74.
10. Davis HF, Skolasky RL Jr, et al. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read. 2002;12:29-31, 38.
11. Smith CA, van Gorp WG, Ryan ER, et al. Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr. 2003;33:116-118.
12. Skinner S, Adewale AJ, DeBlock L, et al. Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy. HIV Med. 2009;10:246-252.
13. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24: 1243-1250.
14. Heaton RK, Miller SW, Taylor MJ, et al. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Scoring Program. Lutz, FL: Psychological Assessment Resources, Inc; 2004.
15. von Giesen HJ, Haslinger BA, Rohe S, et al. HIV Dementia Scale and psychomotor slowing-the best methods in screening for neuro-AIDS. J Neuropsychiatry Clin Neurosci. 2005;17:185-191.
16. Morgan EE, Woods SP, Scott JC, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol. 2008;30:83-90.
17. Benton AL, Hanmsher KS, Sivan AB. Multilingual Aphasia Examination. 3rd ed. Iowa City, IA: AJA Associates, Inc; 1994.
18. Gladsjo JA, Schuman CC, Evans JD, et al. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 1999;6:147-178.
19. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York, NY: Oxford University Press; 2006.
20. Psychological Corporation. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: Psychological Corportation; 1997.
21. Reitan R. Manual for Administration of Neuropsychological Test Batteries for Adults and Children. Tucson, AR: Neuropsychology Laboratory; 1979.
22. Kongs SK, Thompson LL, Iverson GL, Heaton RK. Wisconsin Card Sorting Test-64 Card Computerized Version. Odessa, FL: Psychological Assessment Resources; 2000.
23. Diehr MC, Cherner M, Wolfson TJ, et al. The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples. J Clin Exp Neuropsychol. 2003;25: 571-585.
24. Kløve H. Grooved Pegboard. Lafayette, IN: Lafayette Instruments; 1963.
25. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol. 2004;26:759-778.
26. Martin EM, Novak RM, Fendrich M, et al. Stroop performance in drug users classified by HIV and hepatitis C virus serostatus. J Int Neuropsychol Soc. 2004;10:298-300.
27. von Giesen HJ, Heintges T, Abbasi-Boroudjeni N, et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr. 2004;35:131-137.
28. Clifford DB, Evans SR, Yang Y, et al. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS. 2005;19(suppl 3):S64-S71.
29. Parsons TD, Tucker KA, Hall CD, et al. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection. AIDS. 2006;20: 1591-1595.
30. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234-248.
31. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74:1260-1266.
32. Dikmen SS, Heaton RK, Grant I, Temkin NR. Test-retest reliability and practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. J Int Neuropsychol Soc. 1999;5:346-356.
33. Beglinger LJ, Gaydos B, Tangphao-Daniels O, et al. Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol. 2005;20:517-529.
34. Palella FJ, Chmiel JS, Moorman AC, et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIVinfected patients. AIDS. 2002;16:1617-1626.
35. Paredes R, Mocroft A, Kirk O, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe-results from the EuroSIDA Study. Arch Intern Med. 2000;160:1123-1132.
36. Yehia BR, Fleishman JA, Metlay JP, et al. Sustained Viral Suppression in HIV-Infected Patients Receiving Antiretroviral Therapy. JAMA. 2012; 308:339-342.
37. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320-328.
38. Starace F, Bartoli L, Aloisi MS, et al. Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the Neuro-ICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand. 2002;106:20-26.
39. Moore DJ, Blackstone K, Woods SP, et al. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012;24:1504-1513.
40. Carrico AW. Substance use and HIV disease progression in the HAART era: implications for the primary prevention of HIV. Life Sci. 2011;88: 940-947.
41. Hestad KA, Menon JA, Silalukey-Ngoma M, et al. Sex differences in neuropsychological performance as an effect of human immunodeficiency virus infection: a pilot study in Zambia, Africa. J Nerv MentDis. 2012;200: 336-342.
42. Gupta S, Vaida F, Riggs K, et al. Neuropsychological performance in mainland china: the effect of urban/rural residence and self-reported daily academic skill use. J Int Neuropsychol Soc. 2011;17:163-173.